Roche to buy clinical-stage biotechnology firm Promedior in $1.39bn deal

This article was originally published here

As per terms of the merger deal, Promedior will secure an upfront cash payment of $390m, as well as additional contingent payments of up to $1bn based on

The post Roche to buy clinical-stage biotechnology firm Promedior in $1.39bn deal appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply